Department of Allied Health Sciences, University of Connecticut, Storrs, CT, United States.
Institute for Systems Genomics, University of Connecticut, Storrs, CT, United States.
Front Immunol. 2024 Jul 12;15:1423488. doi: 10.3389/fimmu.2024.1423488. eCollection 2024.
T cell development in the thymus is dependent on the thymic microenvironment, in which thymic epithelial cells (TECs) are the major component. However, TECs undergo both a qualitative and quantitative loss during aging, which is believed to be the major factor responsible for age-dependent thymic atrophy. FOXN1 plays a critical role in TEC development and adult TECs maintenance. We have previously reported that intrathymic injection of a recombinant (r) protein containing murine FOXN1 and a protein transduction domain increases the number of TECs in mice, leading to enhanced thymopoiesis. However, intrathymic injection may not be an ideal choice for clinical applications. In this study, we produced a rFOXN1 fusion protein containing the N-terminal of CCR9, human FOXN1 and a protein transduction domain. When injected intravenously into 14-month-old mice, the rFOXN1 fusion protein enters the thymus and TECs, and enhances thymopoiesis, resulting in increased T cell generation in the thymus and increased number of T cells in peripheral lymphoid organ. Our results suggest that the rFOXN1 fusion protein has the potential to be used in preventing and treating T cell immunodeficiency in older adults.
胸腺中的 T 细胞发育依赖于胸腺微环境,其中胸腺上皮细胞(TEC)是主要组成部分。然而,TEC 在衰老过程中经历了定性和定量的丧失,这被认为是导致与年龄相关的胸腺萎缩的主要因素。FOXN1 在 TEC 发育和成年 TEC 维持中发挥着关键作用。我们之前曾报道过,在胸腺内注射含有鼠 FOXN1 和蛋白转导结构域的重组(r)蛋白可增加小鼠 TEC 的数量,从而增强胸腺生成。然而,胸腺内注射可能不是临床应用的理想选择。在这项研究中,我们生产了一种含有 CCR9 N 端、人 FOXN1 和蛋白转导结构域的 rFOXN1 融合蛋白。当将 rFOXN1 融合蛋白静脉注射到 14 月龄的小鼠中时,它会进入胸腺和 TEC,并增强胸腺生成,导致胸腺中 T 细胞的生成增加,外周淋巴器官中的 T 细胞数量增加。我们的结果表明,rFOXN1 融合蛋白有可能用于预防和治疗老年人的 T 细胞免疫缺陷。